Validated LC-MS/MS method for simultaneous quantification of KRASG12C inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study

Absorption, Distribution, Metabolism and Excretion of [14C]-Sotorasib in Rats and Dogs: Interspecies Differences in Absorption, Protein Conjugation and Metabolism

(2022) Upendra P. Dahal et al.   DRUG METABOLISM AND DISPOSITION

ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability

(2022) Nancy H.C. Loos et al.   PHARMACOLOGICAL RESEARCH

Absorption, metabolism and excretion of [14C]-sotorasib in healthy male subjects: characterization of metabolites and a minor albumin-sotorasib conjugate

(2022) Irene Vuu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Mercapturate pathway metabolites of sotorasib, a covalent inhibitor of KRASG12C, are associated with renal toxicity in the Sprague Dawley rat

(2021) Jonathan A. Werner et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Nonclinical Safety Profile of Sotorasib, a KRASG12C-Specific Covalent Inhibitor for the Treatment of KRAS p.G12C-Mutated Cancer

(2021) Katsu Ishida et al.   INTERNATIONAL JOURNAL OF TOXICOLOGY

Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry

(2021) Irene A. Retmana et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC

(2021) Erica C. Nakajima et al.   CLINICAL CANCER RESEARCH

Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry

(2019) Burcu Dogan-Topal et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES